Vistagen enrolls first subject in PALISADE-4 Phase 3 trial of fasedienol for SAD

Vistagen Therapeutics, Inc.

First subject enrolled in PALISADE-4 Phase 3 trial of fasedienol nasal spray for acute treatment of social anxiety disorder (SAD).
Fasedienol is an investigational neuroactive pherine candidate in U.S. registration-directed Phase 3 development.
Over 30 million Americans suffer from SAD; no FDA-approved acute treatments currently available.
Fasedienol targets nose-to-brain neural circuits to reduce fear and anxiety associated with SAD.
CEO Shawn Singh confirmed the milestone was achieved as planned in the registration-directed program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.